You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
20 December 2023
iOmx Therapeutics attends 2024 J.P. Morgan Healthcare Conference
1 November 2023
iOmx Therapeutics attends upcoming scientific and industry conferences
5 September 2023
iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer
4 April 2023
iOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trial
23 February 2023
iOmx Therapeutics appoints Dr. Christine Rothe as new Chief Development Officer
7 September 2022
iOmx Therapeutics appoints Professor Frances Balkwill to the Scientific Advisory Board
20 July 2022
iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members
7 April 2022
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
3 February 2022
iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development
5 October 2021
iOmx Therapeutics raises EUR 65 million in Series B round
